Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 653 trials

MSC Therapy for Kidney Transplant Recipients

We are exploring whether a new therapy using stem cells can improve health outcomes for people who have received a kidney transplant. This study aims to understand its potential benefits in this patient group.

Kidney Transplant RejectionBiopsy-Proven Acute Rejection (BPAR)1-2 yearsSafety phase (I)Internal MedicineNephrology

Major Depressive Disorder: Ketamine and ECT Study

We are investigating whether combining ketamine with electroconvulsive therapy helps people with treatment-resistant depression. The study also examines its effects on brain chemicals and cognitive function.

Treatment Resistant DepressionMajor Depressive Disorder1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPsychiatry

Bladder Cancer: ONCOFID-P-B Treatment Study

We are studying a new treatment called ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to standard care. The goal is to see if this treatment can effectively reduce tumors and improve patient outcomes.

Bladder Cancer in Situ1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteOncology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Relapsing Multiple Sclerosis: YTB323 Treatment Study

We are testing a new treatment called YTB323 for people with Relapsing Multiple Sclerosis who have had ongoing disease activity despite previous therapies. The study aims to assess its safety and effects on disease progression.

Relapsing Multiple Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurology

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: Elacestrant and Everolimus Study

We are studying a combination of elacestrant and everolimus for patients with advanced breast cancer that has specific mutations. The goal is to see if this treatment helps delay cancer progression compared to a placebo.

Advanced Estrogen Receptor-Positive Breast Cancer1-2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyOncology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Crohn’s Disease: AZD7798 PET Study

We are examining how different doses of the drug AZD7798 are taken up in the body of patients with Crohn’s disease. This study aims to provide insights into the drug's effects on this condition.

Crohn's Disease1-2 yearsSafety phase (I)Gastroenterology

Frozen Shoulder Treatment: Corticosteroid Injection with Nerve Block

We are studying whether a corticosteroid injection combined with a nerve block provides better pain relief and shoulder function than an injection with a placebo. This trial aims to help improve treatment strategies for patients with Frozen Shoulder.

Frozen ShoulderAdhesive Capsulitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology